Safety, pharmacokinetics and quantitative EEG modulation of TAK-071, a novel muscarinic M1 receptor positive allosteric modulator, in healthy subjects.

Saved in:
Bibliographic Details
Title: Safety, pharmacokinetics and quantitative EEG modulation of TAK-071, a novel muscarinic M1 receptor positive allosteric modulator, in healthy subjects.
Authors: Yin W; Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA., Mamashli F; Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.; Signal Insights, LLC, Cambridge, MA, USA., Buhl DL; Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA., Khudyakov P; Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA., Volfson D; Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA., Martenyi F; Prothena Biosciences, South San Francisco, CA, USA., Gevorkyan H; California Clinical Trials Medical Group, in affiliation with Parexel International, Glendale, CA, USA., Rosen L; Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA., Simen AA; Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
Source: British journal of clinical pharmacology [Br J Clin Pharmacol] 2022 Feb; Vol. 88 (2), pp. 600-612. Date of Electronic Publication: 2021 Jul 31.
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2125 (Electronic) Linking ISSN: 03065251 NLM ISO Abbreviation: Br J Clin Pharmacol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1365-2125
DOI:10.1111/bcp.14975